AlphaYouBR
Schedule 13G filing
BlackRock, Inc. disclosed a 14.1% stake in Arcutis Biotherapeutics, Inc. (ARQT)
BlackRock, Inc. reported owning 14.1% of Arcutis Biotherapeutics, Inc. (ARQT) (17,751,435 shares) in a Schedule 13G filed Oct 5, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Oct 5, 2026
- Source
- Schedule 13G
More ARQT insider and Congress trades
From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.